Provided by Tiger Trade Technology Pte. Ltd.

Incyte

121.74
-0.4500-0.37%
Post-market: 120.26-1.4785-1.21%19:40 EDT
Volume:1.56M
Turnover:189.78M
Market Cap:24.68B
PE:15.51
High:122.19
Open:121.58
Low:119.97
Close:122.19
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.13
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.89
PE(LYR):18.99

Loading ...

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 11

Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program

MT Newswires Live
·
Sep 10

Incyte Announces Funding of Minjuvi® (Tafasitamab) for Patients with Relapsed or Refractory Follicular Lymphoma Through Ontario's Fast Program

THOMSON REUTERS
·
Sep 10

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 09

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 02

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 01

Incyte Reaches CMS Pact on Jakafi Medicaid Pricing

TIPRANKS
·
Sep 01

Incyte - Expects Exemption from Future CMS Pricing Mandates Including Guard and Globe - SEC Filing

THOMSON REUTERS
·
Sep 01

Incyte - Announces Agreement with CMS to Improve Medicine Access - SEC Filing

THOMSON REUTERS
·
Sep 01

Incyte - State Medicaid to Access Jakafi and Jakafi Xr at Prices Aligned with Advanced Nations - SEC Filing

THOMSON REUTERS
·
Sep 01

Incyte - Does not Expect Agreement to Affect 2026 Financial Guidance or Outlook - SEC Filing

THOMSON REUTERS
·
Sep 01

Incyte (INCY) Stock Could Be 31% Stretched Following KRAS Data Buzz

Simply Wall St.
·
Aug 30

US FDA Approves Takeda, Protagonist's Drug for Rare Blood Cancer

Reuters
·
Aug 29

Incyte Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Incyte Corp Drops in Volume Surge, Last Down 3.0%

THOMSON REUTERS
·
Aug 29

Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil

MT Newswires Live
·
Aug 28

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Aug 26

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

KDP, Ultragenyx, Incyte, ProQR, Aurinia Trending With Analysts

TIPRANKS
·
Aug 22

Incyte President, Global Head of R&D Pablo J. Cagnoni Sells 10,801 Shares for $1.36 Million

Reuters
·
Aug 21